In order to strengthen its gene therapy pipeline, Novartis has acquired Kate Therapeutics in a deal worth up to US$1.1 B, comprising an upfront payment and potential additional milestone payments. Through the deal, Novartis picks up access to Kate’s preclinical candidates for Duchenne muscular dystrophy (DMD), facioscapulohumeral dystrophy (FSHD), and myotonic dystrophy type 1 (DM1) as well as its DELIVER and Cargo technology platforms. The acquisition aligns with Novartis’ strategic priorities in gene therapy and neuroscience innovation, as the company remains committed to addressing unmet needs for patients living with inherited neuromuscular diseases.